XTL Biopharma (XTLB) Announces Receipt of NASDAQ Notification Regarding Minimum Bid Requirements
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- AMC Entertainment (AMC) Enters $250M ATM Agreement
XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements
November 9, 2016 1:25 PM ESTRAANANA, Israel, November 9, 2016 /PRNewswire/ --
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead product for the treatment of autoimmune diseases, today announced that it received a notice from The NASDAQ Stock Market ("NASDAQ") that the Company is not in compliance with NASDAQ's Listing Rule 5450(a)(1) because the minimum bid price of the Company's American Depositary Shares ("ADSs") has closed below US$1.00 per share for 30 consecutive business days. The notification of... More